DNTH — Dianthus Therapeutics, Inc. stock price, charts and financials

QT77Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
106.02
-0.90-0.84%
OverviewShort InterestFilings
DNTHQT77Dianthus Therapeutics, Inc.·NASDAQ
106.02-0.84%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ACAD-1.00%$25.61CAI+4.15%$16.32MANE-2.96%$101.89CRSP+3.29%$49.57DYN+0.24%$25.24PRTC+4.51%$17.38CELC+1.55%$87.72DFTX-3.98%$41.79
Snapshot
Index-P/E-EPS (ttm)-2.88Insider Own18.92%Shs Outstand41.75MPerf Week2.94%
Market Cap4.46BForward P/E-EPS next Y-4.48Insider Trans-5.57%Shs Float29.16MPerf Month18.52%
Enterprise Value3.84BPEG-EPS next Q-Inst Own-Short Float31.62%Perf Quarter21.78%
Income-9.82MP/S-EPS this Y-30.17%Inst Trans-Short Ratio9.91Perf Half Y100.37%
Sales1.34MP/B4.28EPS next Y-19.44%ROA-0.91%Short Interest9.22MPerf YTD159.45%
Book/sh-P/C-EPS next 5Y-ROE-1.78%52W High113.58 -6.66%Perf Year414.04%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-15.82%52W Low17.93 491.37%Perf 3Y725.00%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-30.66% -Gross Margin94.31%Volatility6.22% 6.08%Perf 5Y-9.70%
Dividend TTM-EV/Sales-EPS Y/Y TTM-12.94%Oper. Margin-14318.04%ATR (14)6.13Perf 10Y-
Dividend Ex-Date-Quick Ratio29.25Sales Y/Y TTM0.00%Profit Margin-847.53%RSI (14)58.08Recom1.90
Dividend Gr. 3/5Y-Current Ratio29.25EPS Q/Q-3.66%SMA205.16%Beta1.19Target Price115.00
Payout0.00%Debt/Eq0.00Sales Q/Q-100.00%SMA5015.39%Rel Volume1.05Prev Close106.92
Employees92LT Debt/Eq0.00EarningsAug 06SMA20060.44%Avg Volume1.01MPrice106.02
IPO DateJun 21, 2018Option/ShortYes / YesEPS/Sales Surpr.20.70% 14.71%Net Debt/EBITDA57.66Volume1,052,444Change-0.84%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedJefferiesBuy$110 → $132
May-11-26ReiteratedEvercore ISI$122 → $120
May-06-26ReiteratedRaymond JamesStrong Buy$123 → $125
Apr-08-26InitiatedWolfe ResearchOutperform$98
Mar-10-26UpgradeRaymond JamesOutperform → Strong Buy
Mar-09-26ReiteratedUBS$81 → $98
Mar-09-26ReiteratedJefferiesBuy$51 → $98
Mar-09-26ReiteratedRobert W. Baird$67 → $132
Mar-09-26ReiteratedStifel Nicolaus$120
Mar-09-26ReiteratedOppenheimerOutperform$62 → $145
Latest News
Company

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue626361000
Cost of Goods Sold Incl. D&A000000221
Gross Profit626361-2-2-1
Selling, General and Administrative Excl. Other2734251872282418
Research and Development9714683332913495741
Other Operating Expense
-100000000
Operating Income-117-178-102-48-30-13-79-83-60
Interest Expense000000400
Unusual Expense
—————————
Non-Operating Income (Expense)171617510862
Net Income Before Taxes-101-162-85-44-28-13-75-77-58
Income Taxes
000000000
Consolidated Net Income-101-162-85-44-28-13-75-77-58
Net Income From Continuing Operations-101-162-85-44-28-13-75-77-58
Net Income-101-162-85-44-28-13-75-77-58
EPS (Recurring)-2.88-4.20-2.55-8.45-7.60-3.82-27.30-33.18-27.62
EPS (Basic, Before Extraordinaries)-2.88-4.20-2.55-8.45-7.60-3.82-27.30-33.18-27.62
EPS (Diluted)-2.88-4.20-2.55-8.45-7.60-3.82-27.30-33.18-27.62
EBITDA-99-162-85-43-28-11-73-75-57
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio636.12782.99119.9017.334.21212.64———
Gross Margin100.00100.00100.00100.00100.00100.00———
Operating Margin-1,950.00-8,900.00-1,700.00-1,600.00-500.00-1,300.00———
Net Margin-1,683.33-8,100.00-1,416.67-1,466.67-466.67-1,300.00———
Shares Outstanding363833543322
Market Capitalization3,8171,5667195225213376485182
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$127.01$95.88$64.75$33.62$2.49● Close Price0.00M7.01M14.01M21.02M28.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Savitz RyanEVP, CFO & CBOJul 09 '26Sale101.0331,2493,157,1510Jul 13
Savitz RyanEVP, CFO & CBOJul 09 '26Option Exercise21.7731,249680,29131,249Jul 13
Veness Adam MSVP, General Counsel and Sec.Jun 17 '26Option Exercise17.8830,000536,40030,000Jun 18
Veness Adam MSVP, General Counsel and Sec.Jun 17 '26Sale80.8030,0002,423,9580Jun 18
Randhawa SimratEVP, Head of R&DJun 01 '26Option Exercise18.8526,530500,20530,530Jun 02
Randhawa SimratEVP, Head of R&DJun 01 '26Sale90.6226,5302,404,0774,000Jun 02
Soteropoulos PaulaDirectorMay 08 '26Option Exercise8.445995,056599May 11
Soteropoulos PaulaDirectorMay 08 '26Sale85.4759951,1970May 11
Savitz RyanEVP, CFO & CBOApr 09 '26Option Exercise17.888,224147,0458,224Apr 10
Savitz RyanEVP, CFO & CBOApr 09 '26Sale89.848,224738,8440Apr 10
Savitz RyanEVP, CFO & CBOMar 31 '26Option Exercise11.74114,3671,342,857114,367Apr 01
Savitz RyanEVP, CFO & CBOMar 31 '26Sale83.00114,3679,492,5950Apr 01
Soteropoulos PaulaDirectorMar 31 '26Option Exercise8.445995,056599Apr 01
Soteropoulos PaulaDirectorMar 31 '26Sale80.1159947,9860Apr 01
Soteropoulos PaulaDirectorMar 24 '26Option Exercise8.4427,594232,89327,594Mar 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.